Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | $42.07M |
| Net Income (Most Recent Fiscal Year) | $-130.30M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 13.14 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -322.17% |
| Net Margin (Trailing 12 Months) | -322.67% |
| Return on Equity (Trailing 12 Months) | -62.75% |
| Return on Assets (Trailing 12 Months) | -39.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.86 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.19 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.22 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 108.39M |
| Free Float | 100.26M |
| Market Capitalization | $538.72M |
| Average Volume (Last 20 Days) | 3.90M |
| Beta (Past 60 Months) | 1.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.99% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |